More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026

Data ReadoutpositiveLeqembiPositive

AI Analysis

Summary

Eisai presented positive real-world LEADER study data for Leqembi showing 83% of early Alzheimer's disease patients remained stable or improved over 17 months of treatment. The results demonstrate clinical benefit in real-world settings for the lecanemab treatment.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

LEADER real-world study showed 83% of patients with early AD were stable or improved, with 75% remaining stable and nearly 7% improved over average 17 months of treatment

Importance:7/10

Sentiment:

0.80

Alzheimer's diseasereal-world datamonoclonal antibodyclinical outcomesneurology

Related Companies

$BIOA-B.ST $ESALY

Read the original article

Published by PR Newswire Biotech on July 14, 2026 3:41 PM

Read Original